Huang Menghao, Jiang Jian-Dong, Peng Zonggen
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China ; Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Acta Pharm Sin B. 2014 Aug;4(4):241-7. doi: 10.1016/j.apsb.2014.06.010. Epub 2014 Jul 14.
Interferon (IFN) in combination with ribavirin has been the standard of care (SOC) for chronic hepatitis C for the past few decades. Although the current SOC lacks the desired efficacy, and 4 new direct-acting antiviral agents have been recently approved, interferons are still likely to remain the cornerstone of therapy for some time. Moreover, as an important cytokine system of innate immunity, host interferon signaling provides a powerful antiviral response. Nevertheless, the mechanisms by which HCV infection controls interferon production, and how interferons, in turn, trigger anti-HCV activities as well as control the outcome of HCV infection remain to be clarified. In this report, we review current progress in understanding the mechanisms of IFN against HCV, and also summarize the knowledge of induction of interferon signaling by HCV infection.
在过去几十年中,干扰素(IFN)联合利巴韦林一直是慢性丙型肝炎的标准治疗方案(SOC)。尽管目前的标准治疗方案疗效不尽人意,且最近已批准了4种新型直接抗病毒药物,但干扰素在一段时间内仍可能是治疗的基石。此外,作为天然免疫的重要细胞因子系统,宿主干扰素信号传导可提供强大的抗病毒反应。然而,HCV感染控制干扰素产生的机制,以及干扰素如何反过来触发抗HCV活性并控制HCV感染的结果仍有待阐明。在本报告中,我们综述了目前在理解IFN抗HCV机制方面的进展,并总结了HCV感染诱导干扰素信号传导的相关知识。